Compare · DXCM vs SIBN
DXCM vs SIBN
Side-by-side comparison of DexCom Inc. (DXCM) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 38.4x SIBN ($770.8M).
- Over the past year, DXCM is down 8.7% and SIBN is up 2.2% - SIBN leads by 10.9 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 3 for SIBN).
- DXCM has more recent analyst coverage (25 ratings vs 11 for SIBN).
- Company
- DexCom Inc.
- SI-BONE Inc.
- Price
- $76.58-0.09%
- $17.01-2.07%
- Market cap
- $29.58B
- $770.8M
- 1M return
- +7.73%
- +11.83%
- 1Y return
- -8.69%
- +2.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2018
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 11
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest SIBN
- ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $52,375 worth of shares (3,134 units at $16.71), decreasing direct ownership by 1% to 277,375 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Maheshwari Anshul sold $55,627 worth of shares (3,317 units at $16.77), decreasing direct ownership by 1% to 256,560 units (SEC Form 4) to cover withholding tax
- Director Hilleman Jeryl L was granted 10,957 shares, increasing direct ownership by 33% to 43,772 units (SEC Form 4)
- Director Dunn Jeffrey W was granted 10,957 shares and sold $54,505 worth of shares (3,575 units at $15.25), increasing direct ownership by 75% to 16,057 units (SEC Form 4) to cover withholding tax
- Director Nishimura Mika was granted 10,957 shares, increasing direct ownership by 33% to 43,673 units (SEC Form 4)
- Director West Thomas A. was granted 10,957 shares, increasing direct ownership by 41% to 37,947 units (SEC Form 4)
- Director Freund John Gordon was granted 10,957 shares, increasing direct ownership by 25% to 54,258 units (SEC Form 4)
- Director Davis Timothy E Jr was granted 10,957 shares, increasing direct ownership by 17% to 76,679 units (SEC Form 4)
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits